<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="1275">
  <stage>Registered</stage>
  <submitdate>17/05/2006</submitdate>
  <approvaldate>7/06/2006</approvaldate>
  <actrnumber>ACTRN12606000231549</actrnumber>
  <trial_identification>
    <studytitle>Pharmacokinetics and pharmacodynamics of high dose melphalan in myeloma patients undergoing an autograft.</studytitle>
    <scientifictitle>Using blood melphalan concentrations to reduce toxicity and improve outcome in myeloma autograft recipients</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Cancer Trials NSW: PK-10-01</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Multiple myeloma</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Myeloma</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>This is a multi-institutional study in which a single high dose of melphalan will be administered intravenously over 30 minutes and plasma melphalan concentrations will be measured following the dose to see whether there is a relationship with disease response or toxicity post transplant.. The standard melphalan dose is 200 mg/m2, but some patients will have reduced doses due to renal dysfunction or obesity and this will be according to existing protocols at each participating institution. This is an observational study with no control group.</interventions>
    <comparator>No control group.</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>1. We will be establishing the pharmacokinetics of melphalan in a large population of patients with myeloma. Total exposure (or area-under-the-concentration-versus-time curve, AUC) and other pharmacokinetic parameters will be determined for each individual using the blood concentrations.</outcome>
      <timepoint>Measured after a single dose. </timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>2. Data about the patient (e.g. weight, height, surface area, renal function, laboratory values, disease stage and other details, prior chemotherapy) to allow an assessment of the factors that may contribute to the variability in melphalan pharmacokinetic parameters and transplant outcome. </outcome>
      <timepoint>Collected prior to the melphalan dose and autologous transplant, on study enrolment.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>3. Transplant related toxicity including mucositis, gastrointestinal toxicity, haematological toxicity, and other toxicities</outcome>
      <timepoint>Followed for up to 4 weeks post the melphalan dose and autologous transplant. </timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>4. Disease response and survival</outcome>
      <timepoint>Followed for up to 2 years post transplant. </timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>5. Statistical methods will be used to identify a target AUC range that is associated with a good outcome with acceptable toxicity. </outcome>
      <timepoint>Analysis will be performed when data on all 140 patients has been collected. This will be approximately 2 years after the transplant date of the last patient recruited into the study.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>6. The population pharmacokinetic model can then be used to design a dosing schedule the will aim to provide patients, including those who are heavy or who have renal impairment, with an AUC within the target range to provide the optimal outcome.</outcome>
      <timepoint>When data from 60 patients has been collected. This analysis is currently being performed.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Nil</outcome>
      <timepoint>Nil</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>All myeloma patients scheduled to receive high dose melphalan followed by an autologous transplant. </inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>The only patients that will be exluded from the study are those unable to give informed consent.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Pharmacokinetics / pharmacodynamics</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>1/01/2006</anticipatedstartdate>
    <actualstartdate>21/04/2004</actualstartdate>
    <anticipatedenddate />
    <actualenddate>29/06/2010</actualenddate>
    <samplesize>140</samplesize>
    <actualsamplesize>120</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/08/2013</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <postcode>61</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>The Childrens Hospital at Westmead</primarysponsorname>
    <primarysponsoraddress>Hawkesbury Rd. Westmead, NSW, 2145</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>NHMRC project grant 396702</fundingname>
      <fundingaddress>MDP 70, 
GPO Box 9848
Canberra, ACT, 2601</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Hospital</sponsortype>
      <sponsorname>Concord Hospital</sponsorname>
      <sponsoraddress>Hospital Rd. 
Concord, NSW, 2139</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
    <secondarysponsor>
      <sponsortype>Other Collaborative groups</sponsortype>
      <sponsorname>Cancer Trials NSW</sponsorname>
      <sponsoraddress>153 Dowling St.
Woolloomooloo,
NSW, 2011</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study is measuring blood levels of the medication melphalan to improve the way to adjust the dose for people with myeloma. 
Who is it for?
You can join the this study if you have myeloma (a cancer which affects plasma cells in the bone marrow) and are undergoing a bone marrow transplant. 
Trial details
Participants will receive the drug melphalan and will be tested to see how their body breaks down and gets rid of the medication. 
This study does not replace other studies, but simply investigates key medication widely used in the treatment of myeloma. Participants will be followed for several years after the study to monitor their health. 
This study will help to define the best way to adjust doses of the drug melphalan, a key medication in helping to control myeloma. Too much causes toxicity and too little risks the disease being more likely to return.</summary>
    <trialwebsite />
    <publication>SCIENTIFIC PUBLICATIONS
1.	Nath CE, Trotman J, Tiley C, Presgrave P,  Joshua D, Kerridge I, Kwan YL, Gurney H, McLachlan A, Earl J, Nivison-Smith I, Zeng L, Shaw PJ. High melphalan exposure is associated with improved overall survival in myeloma patients receiving high dose melphalan and autologous transplantation. Br J. Clin Pharmacol. 2016, 82: 149-159.
2. Nath CE, Shaw PJ, Trotman J, Zeng L, Duffull SB, Hegarty G, McLachlan AJ, Gurney H, Kerridge I, Kwan Y, Presgrave P, Tiley C, Joshua D, Earl J. (2010) Population pharmacokinetics of melphalan in patients with multiple myeloma undergoing high dose therapy. British Journal of Clinical Pharmacology. 69: 484  497.
3. Nath CE, Zeng L, Eslick A, Trotman J and Earl J. (2008) An isocratic UV HPLC Assay for the determination of total and free melphalan concentrations in human plasma. Acta Chromatographica. 20(3); 383  398. 
4. Nath CE, Shaw PJ, Trotman J and Zeng L. (2007) Pharmacokinetics of melphalan in myeloma patients undergoing an autograft. Bone Marrow Transplant. 40: 707  708.

Conference Presentations

1. Shaw PJ, Nath CE, Nivison-Smith I, Joshua DE, Kerridge IH, Presgrave P, Tiley CR, Kwan YL and Trotman J. Higher Melphalan exposure is associated with improved overall survival for myeloma patients undergoing autologous transplant. Biol Blood Marrow Transplant (2012) : 18 (2) Suppl 2 Pages: S207 Meeting Abstract: 13 
2. PJ Shaw, CE Nath, J Trotman, H Gurney, L Zeng, Y Kwan, P Presgrave, C Tiley, D Joshua, I Kerridge, AJ McLachlan, JW Earl. Actual weight to calculate surface area provides the best estimate for AUC in myeloma. ASBMT Feb 2010. Biol Blood Marrow Transplant 2010; 16(2): S180. DOI: 10.1016/j.bbmt.2009.12.088.
3. SB Duffull, G Hegarty, CE Nath, PJ Shaw and J Trotman. Evaluation of an optimal design for examining melphalan pharmacokinetics in patients with multiple myeloma. PAGANZ Feb 2010. 
4. CE Nath, PJ Shaw , J Trotman , L Zeng, S Duffull, AJ McLachlan, H Gurney , Y Kwan, P Presgrave, C Tiley, D Joshua, I Kerridge and J Earl. Population pharmacokinetics of melphalan in patients with multiple myeloma. PAGANZ Feb 2010. 
5. CE Nath, PJ Shaw, J Trotman, L Zeng, S Duffull, AJ McLachlan, H Gurney, I Kerridge, Y Kwan, P Presgrave, C Tiley, D Joshua, JW Earl, Renal function, haematocrit and body size affect total and unbound melphalan clearance in patients with multiple myeloma. ASCEPT. December 2009. Sydney. 
6. Nath CE, Shaw PJ, Trotman J, Zeng L , Joshua D, Kerridge I, Kwan Y, Presgrave P, Tiley C, McLachlan AJ, Gurney H, Earl JW. Pharmacodynamics of high dose melphalan in myeloma. CLINICAL LYMPHOMA &amp; MYELOMA Volume: 9 Pages: S34-S35 Supplement: Suppl. 1. Feb 2009. 12th International Myeloma Workshop. USA.
7. Nath CE, Shaw PJ, Trotman J, Zeng L, Tiley C, Joshua D, Kerridge I, Kwan Y, Presgrave P, Gurney H, McLachlan AJ and Earl JW. (2008). Optimising High Dose Melphalan in patients with multiple Myeloma: Preliminary results from a multi-centre trial. Invited oral presentation at Ehrlich II Conference in Nuremburg in October. Awarded the Paul Ehrlich Magic Bullet Award 2008.
8. Nath CE, Shaw PJ, Trotman J, Zeng L, Gurney H, McLachlan AJ, Presgrave P, Tiley C, Joshua D, Kerridge I, Kwan Y and Earl J (2008). Population pharmacokinetics of melphalan in myeloma patients. Poster presentation at AAPS, Atlanta, USA. 
9. Nath CE, Shaw PJ, Trotman J, Zeng L, McLachlan AJ, Gurney H, Kwan YL, Presgrave P, Tiley C, Joshua D, Kerridge I, Kwan YL and Earl J. (2008).Population pharmacokinetics of melphalan in myeloma patients. AACB conference. Newcastle. 
10. Nath CE, Shaw PJ, Trotman J, Zeng L, McLachlan AJ, Gurney H, Kwan YL, Presgrave P, Tiley C, Joshua D, Kerridge I and Earl J. (2008) Population pharmacokinetics of melphalan in myeloma patients. ASMR, Sydney. 
11. Nath CE, Shaw PJ, Trotman J, Zeng L, Gurney H, McLachlan AJ, Kerridge I, Kwan Y, Presgrave P, Tiley C, Joshua D and Earl J (2008) Population pharmacokinetics of melphalan in myeloma patients undergoing an autograft. PAGANZ (Dunedin, New Zealand).
12. Nath CE, Shaw PJ, Trotman J, Zeng L, Joshua D, Kerridge I, Presgrave P, Kwan YL, Tiley C, Nivivon-Smith I, McLachlan AJ, gurney H, Booth A and Earl JW. (2007). Melphalan pharmacokinetics in myeloma. XIth International Myeloma Workshop. Haematologica - The hematology journal; 92: (6): 188 (Suppl.2).
</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Concord Hospital</ethicname>
      <ethicaddress>Hospital Rd. 
Concord, NSW, 2139</ethicaddress>
      <ethicapprovaldate>16/03/2004</ethicapprovaldate>
      <hrec>CH62/6/2004-016</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Wollongong Hospital</ethicname>
      <ethicaddress>Loftus St.
Wollongong, 
NSW, 2500</ethicaddress>
      <ethicapprovaldate>5/04/2005</ethicapprovaldate>
      <hrec>HE05/075</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Prince Alfred Hospital</ethicname>
      <ethicaddress>Missenden Rd. 
Camperdown, NSW, 2050</ethicaddress>
      <ethicapprovaldate>2/06/2004</ethicapprovaldate>
      <hrec>X04-0105</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>St George Hospital</ethicname>
      <ethicaddress>South St. 
Kogarah, 
NSW, 2217</ethicaddress>
      <ethicapprovaldate>8/02/2005</ethicapprovaldate>
      <hrec>05/06</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Westmead Hospital</ethicname>
      <ethicaddress>Hawkesbury Rd.
Westmead, NSW, 2145</ethicaddress>
      <ethicapprovaldate>9/06/2004</ethicapprovaldate>
      <hrec>2004/4/4.13(1831)</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Gosford Hospital</ethicname>
      <ethicaddress>Cnr Holden Street and Racecourse Road, GOSFORD NSW 2250</ethicaddress>
      <ethicapprovaldate>19/01/2006</ethicapprovaldate>
      <hrec>05/65</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Christa Nath</name>
      <address>Department of Biochemistry
The Childrens Hospital at Westmead
Hawkesbury Rd
Locked Bag 4001
Westmead NSW 2145</address>
      <phone>+61 2 98453287</phone>
      <fax>+61 2 98453332</fax>
      <email>christa.nath@health.nsw.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Christa Nath</name>
      <address>Department of Biochemistry
The Childrens Hospital at Westmead
Hawkesbury Rd
Locked Bag 4001
Westmead NSW 2145</address>
      <phone>+61 2 98453287</phone>
      <fax>+61 2 98453332</fax>
      <email>christa.nath@health.nsw.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Christa Nath</name>
      <address>Department of Biochemistry, 
The Childrens Hospital at Westmead, 
Hawkesbury Rd. 
Westmead, NSW, 2145</address>
      <phone>+61 2 98453287</phone>
      <fax>+61 2 98453332</fax>
      <email>christa.nath@health.nsw.gov.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Judith Trotman</name>
      <address>Department of Haematology,
Concord Hospital, 
Hospital Rd,
Concord, 2139</address>
      <phone>61-2-97675000</phone>
      <fax />
      <email>Judith.Trotman@sswahs.nsw.gov.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>